A detailed history of Black Rock Inc. transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,905,160 shares of PSTX stock, worth $13.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,905,160
Previous 4,950,070 0.91%
Holding current value
$13.5 Million
Previous $15.8 Million 9.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.0 - $3.46 $89,820 - $155,388
-44,910 Reduced 0.91%
4,905,160 $14.3 Million
Q1 2024

May 10, 2024

SELL
$2.76 - $4.13 $223,844 - $334,955
-81,103 Reduced 1.61%
4,950,070 $15.8 Million
Q4 2023

Feb 13, 2024

SELL
$1.83 - $3.51 $39,904 - $76,539
-21,806 Reduced 0.43%
5,031,173 $16.9 Million
Q3 2023

Nov 13, 2023

SELL
$1.62 - $2.79 $212,683 - $366,287
-131,286 Reduced 2.53%
5,052,979 $12 Million
Q2 2023

Aug 11, 2023

BUY
$1.66 - $3.4 $5.47 Million - $11.2 Million
3,294,442 Added 174.33%
5,184,265 $9.12 Million
Q1 2023

May 12, 2023

BUY
$3.08 - $8.73 $525,906 - $1.49 Million
170,749 Added 9.93%
1,889,823 $5.82 Million
Q4 2022

Feb 13, 2023

BUY
$3.33 - $6.38 $902,949 - $1.73 Million
271,156 Added 18.73%
1,719,074 $9.11 Million
Q3 2022

Nov 14, 2022

BUY
$2.43 - $4.51 $804,779 - $1.49 Million
331,185 Added 29.66%
1,447,918 $5.11 Million
Q2 2022

Aug 12, 2022

SELL
$1.87 - $5.0 $2.53 Million - $6.76 Million
-1,352,221 Reduced 54.77%
1,116,733 $2.88 Million
Q1 2022

May 12, 2022

SELL
$3.22 - $7.04 $270,595 - $591,613
-84,036 Reduced 3.29%
2,468,954 $11.1 Million
Q4 2021

Feb 10, 2022

BUY
$6.23 - $7.6 $123,671 - $150,867
19,851 Added 0.78%
2,552,990 $17.4 Million
Q3 2021

Nov 09, 2021

SELL
$7.09 - $10.71 $61,583 - $93,027
-8,686 Reduced 0.34%
2,533,139 $18.5 Million
Q2 2021

Aug 11, 2021

BUY
$7.96 - $10.07 $20.2 Million - $25.6 Million
2,541,825 New
2,541,825 $25.5 Million

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $237M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.